Incruse Ellipta is an inhaled medication that is used to treat Chronic Obstructive Pulmonary Disease (COPD). COPD is a group of chronic diseases that includeschronic bronchitisandemphysema. The symptoms of COPD are progressive and can include shortness of breath, chronic cough, and wheezing. Incruse Ellipta works by stopping acetylcholine, a neurotransmitter, from activating muscarinic receptors in the smooth muscle of the lungs. This effect causes bronchodilation, which is the relaxation of the airways, and makes it easier to breathe. Fact Table Formula C29H34BrNO2 License EU EMA Bioavailability 13% Legal status Rx-only Chemical Name Umeclidinium Elimination half-life 11 hours Dosage (Strength) 55mcg Pregnancy Consult Doctor Brands Incruse Ellipta Protein binding ~89% PubChem CID 11519069 MedlinePlus a614024 ChEBI 79040 ATC code R03BB07 DrugBank DB09076 KEGG D10181 Routes of administration Inhalation